Reply to Letters to the Editor by Mimura et al. and Hu and Yang regarding the NATALEE final invasive disease-free survival analysis

We read with interest the letters by Mimura et al.1 and Hu and Yang2 in response to the NATALEE final invasive disease-free survival (iDFS) analysis.3 In relation to the authors’ points about treatment benefit, an updated analysis of NATALEE (median follow-up, 44.2 months), conducted with all patients off ribociclib, demonstrated that the iDFS benefit (hazard ratio 0.715; 95% confidence interval…